EUVIMEDEUVIMED entdecken
Open Access

Omaveloxolone, But Not Dimethyl Fumarate, Improves Cardiac Function in Friedreich's Ataxia Mice With Severe Cardiomyopathy

Lili Salinas iD, Francisco Figueroa iD, Claire B Montgomery iD, Phung N Thai iD, Nipavan Chiamvimonvat iD, Gino Cortopassi iD, Elena N Dedkova iD

Journal of the American Heart Association · 2025

DOI: 10.1161/jaha.124.038505 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Lili Salinas und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biosciences University of California Davis CA USA. Hauptthemen laut MEDLINE: Cardiomyopathies, Friedreich Ataxia, Dimethyl Fumarate, Hydroxylamines. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Friedreich's ataxia (FA) is a genetic disorder caused by a severe decrease in FXN (frataxin) protein expression in mitochondria. The clinical manifestation of this disorder is a cerebellar ataxia; however, the common lethal component in FA is cardiomyopathy.

Methods

A conditional Fxn flox/null ::MCK‐Cre knockout (FXN‐cKO) mouse model was used to mimic the late‐stage severe cardiomyopathy in FA. Nrf2 (nuclear factor erythroid 2‐related factor 2) inducers, omaveloxolone and dimethyl fumarate (DMF), were independently tested in this mouse model to determine the effects on cardiac health and lifespan.

Results

Omaveloxolone significantly improved cardiac contractile function and markers of heart failure in FA such as Nppb , Aldh1a3 , and Gdf15 . Despite improvement in cardiac function, omaveloxolone did not prevent premature death in FXN‐cKO animals and notably accelerated death in FXN‐cKO females. Omaveloxolone decreased oxidative stress and inflammatory marker IL1β (interleukin‐1 beta), and stimulated Nqo1 gene expression above control level. DMF restored elevated HO‐1 ( Hmox ) expression and significantly increased Sirt1 expression. Although both omaveloxolone and DMF restored decreased SERCA2 ( Atp2a) and MCU ( Mcu ) expression and ameliorated elevated phosphorylation of CaMKIIδ at Thr 286 site in FA hearts, DMF did not improve cardiac contractile function and survival. Furthermore, neither omaveloxolone or DMF decreased hypertrophy and fibrosis (Masson trichrome staining and Lgals3 expression) or rescued impaired mitochondrial function and integrative stress response in FXN‐cKO hearts.

Conclusions

These data demonstrate that omaveloxolone significantly improved contractile function but not survival in FA hearts because cardiac fibrosis and wall stress persisted even with omaveloxolone treatment. More studies are warranted to determine the cause of premature death in omaveloxolone‐treated FXN‐cKO female mice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CardiomyopathiesFriedreich AtaxiaDimethyl FumarateHydroxylaminesMyocardial ContractionVentricular Function, LeftAnimalsDisease Models, AnimalOxidative StressFemaleMice, KnockoutNF-E2-Related Factor 2MiceMaleSirtuin 1Triterpenes

Stichwörter der Autor:innen

Friedreich's ataxiaanimal models of human diseasecalcium signalingcardiomyopathydimethyl fumarateomaveloxolone

Substanzen

Dimethyl FumarateomaveloxoloneNF-E2-Related Factor 2Nfe2l2 protein, mouseHydroxylaminesSirtuin 1Triterpenes

Autor:innen und Institutionen

  • Department of Molecular Biosciences University of California Davis CA USA.
  • Department of Internal Medicine, Cardiovascular Medicine University of California Davis CA USA.
  • Department of Veterans Affairs Northern California Health Care System Mather CA USA.
  • Department of Basic Sciences California Northstate University Elk Grove CA USA.

ORCID-Profile: Lili Salinas, Francisco Figueroa, Claire B Montgomery, Phung N Thai, Nipavan Chiamvimonvat, Gino Cortopassi, Elena N Dedkova

Förderung

  • NHLBI NIH HHS
  • NIH HHS

Zitieren

APA

Salinas, L., Figueroa, F., Montgomery, C. B., Thai, P. N., Chiamvimonvat, N., Cortopassi, G., & Dedkova, E. N. (2025). Omaveloxolone, But Not Dimethyl Fumarate, Improves Cardiac Function in Friedreich's Ataxia Mice With Severe Cardiomyopathy. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.038505

Vancouver

Salinas L, Figueroa F, Montgomery CB, Thai PN, Chiamvimonvat N, Cortopassi G, et al. Omaveloxolone, But Not Dimethyl Fumarate, Improves Cardiac Function in Friedreich's Ataxia Mice With Severe Cardiomyopathy. Journal of the American Heart Association. 2025. doi:10.1161/jaha.124.038505

BibTeX
@article{Salinas2025,
  author = {Salinas, Lili and Figueroa, Francisco and Montgomery, Claire B and Thai, Phung N and Chiamvimonvat, Nipavan and Cortopassi, Gino and Dedkova, Elena N},
  title = {Omaveloxolone, But Not Dimethyl Fumarate, Improves Cardiac Function in Friedreich's Ataxia Mice With Severe Cardiomyopathy},
  journal = {Journal of the American Heart Association},
  year = {2025},
  doi = {10.1161/jaha.124.038505}
}
Kostenlos starten →